TAG-72 CAR T

TAG-72 CAR T is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy designed to target Tumor-Associated Glycoprotein 72 (TAG-72), a pan-adenocarcinoma oncofetal antigen highly expressed on the surface of various solid tumors, including ovarian, colorectal, breast, and pancreatic cancers. Developed primarily by City of Hope, the therapy involves genetically engineering a patient's own T cells to express a CAR construct. This construct typically features a humanized single-chain variable fragment (scFv) derived from the CC49 or B72.3 antibodies, which provides high-affinity binding to TAG-72, linked to intracellular signaling domains such as CD3-zeta and co-stimulatory domains like 4-1BB (CD137) or CD28. The therapy is currently being evaluated in Phase 1 clinical trials for advanced epithelial ovarian cancer and has been studied in metastatic colorectal cancer, aiming to overcome the challenges of the immunosuppressive tumor microenvironment in solid malignancies.

Other names

TAG-72-directed CAR T-cell therapyTAG72-directed CAR T-cell therapyTAG 72-directed CAR T-cell therapyanti-TAG-72 CAR Tanti-TAG72 CAR Tanti-TAG 72 CAR TTAG72-specific CAR T cellsTAG-72-specific CAR T cellsTAG 72-specific CAR T cells